The role of fulvestrant combined with trastuzumab

Trastuzumab (Trastuzumab) and fulvestrant (Pertuzumab) are two targeted therapies commonly used to treat HER2-positive breast cancer. They can be used in combination to enhance the therapeutic effect. Fulvestrant and trastuzumab are both HER2-targeting antibodies. Fulvestrant binds to the HER2 receptor and blocks the binding of HER2 to ligands in other signaling pathways, thereby inhibiting the proliferation and growth of HER2-positive tumor cells.

Trastuzumab binds toHER2 receptor, preventing its activation and inducing tumor cell apoptosis. Fulvestrant can also prevent the dimerization process by inhibiting the binding between HER2 and HER3. This can further interfere with HER2 signaling and enhance the effect of targeted therapy. Trastuzumab activates natural immune cells to attack tumor cells. The combined use of fulvestrant and trastuzumab can enhance the immune stimulation effect and further improve the therapeutic effect on HER2-positive tumors. The combination of fulvestrant and trastuzumab has shown improved efficacy and survival benefits in the treatment of early and advanced HER2-positive breast cancer. This combination treatment regimen is approved for the treatment of HER2-positive breast cancer.

Trastuzumab is sold under the brand name Herceptin in China and has entered the scope of Class B medical insurance, but it may be limited to patients who meet the indications for this drug, such as patients with HER2-positive metastatic breast cancer and its adjuvant and neoadjuvant treatment or HER2-positive metastatic gastric cancer. The price is around 6,000 yuan. The original trastuzumab drug has also been launched overseas. The drug ingredients of domestic and foreign original drugs are basically the same. For specific prices and drug details, you can consult the medical consultant. There is currently no generic drug of trastuzumab on the market.